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Aims Neladenoson bialanate is a partial adenosine A1 receptor agonist with demonstrated beneficial effects on cardiac
function in animal models.We aimed to assess the dose–response effect of neladenoson bialanate on cardiac structure
and function, clinical outcome, and safety in patients with heart failure (HF) with reduced ejection fraction (HFrEF).
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Methods
and results
PANTHEON was a dose-finding, phase IIb, randomized, double-blind, placebo-controlled trial conducted in 92 cen-
tres in 11 countries including 462 patients with chronic HFrEF, randomized to once daily oral dose of neladenoson
bialanate (5, 10, 20, 30, and 40mg) or placebo. The primary endpoints were change from baseline to 20weeks
in left ventricular ejection fraction (LVEF) (echocardiography) and in N-terminal pro-B-type natriuretic peptide
(NT-proBNP). Mean age of the patients was 67 years, 17% were female, mean LVEF was 28%, mean NT-proBNP
was 2085 ng/L. After 20weeks of treatment, there was no dose–effect of neladenoson bialanate on changes in
NT-proBNP or LVEF (primary endpoints). No effect of neladenoson bialanate was found on left ventricular volumes,
high-sensitivity troponin T, or cardiovascular mortality, HF hospitalization, and urgent visits for HF (secondary
endpoints). There was a dose-dependent increase in creatinine and cystatin C, and a dose-dependent decrease in
estimated glomerular filtration rate and heart rate.
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Conclusions In patients with chronic HFrEF, treatment with neladenoson bialanate was not associated with dose-dependent
favourable effects on cardiac structure and function, cardiac risk markers, or clinical outcome but was associated
with a dose-dependent decrease in renal function.
Clinical Trial Registration: ClinicalTrials.gov identifier NCT02992288.
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Keywords Heart failure • Adenosine • Partial adenosine A1 agonist • Cardiac contractility •
Renal function
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Introduction
Adenosine is ubiquitously present in the entire body and is acti-
vated in response to stress to protect against organ and tissue
damage. In the heart, activation of adenosine A1 receptors mod-
ulates ischaemic injury, arrhythmogenesis, coronary and ventric-
ular dysfunction, apoptosis, mitochondrial dysfunction, and ven-
tricular remodelling.1 Heart failure (HF) with reduced ejection
fraction (HFrEF) is characterized by impaired mitochondrial func-
tion and impaired calcium handling due to a decreased activity
of sarcoplasmic reticulum Ca2+-ATPase (SERCA2a). Activation of
adenosine A1 receptors in the heart results in improved mitochon-
drial function and sarcoplasmic SERCA2 activity and modulates
energy substrate utilization.2 Therefore, adenosine A1 receptor
agonists may be beneficial in patients with HF. Full A1 receptor
agonists can provoke undesired cardiac effects, in particular higher
degree atrioventricular (AV) blocks. In addition, full adenosine A1
receptor agonists can impair renal function due to vasoconstric-
tion of the afferent arterioles.3 Partial agonists might limit the
undesired cardiac conduction disorders and renal effects while pre-
serving beneficial effects on the heart. Preclinical studies showed
that a partial adenosine A1 receptor agonist improved cardiac
function at doses that did not have undesirable effects on heart
rate, AV conduction, and blood pressure.1,4 The safety and tol-
erability of the partial adenosine A1 receptor agonist neladeno-
son bialanate was studied in two small pilot studies in patients
with HFrEF.5 In these studies, neladenoson bialanate was safe
and well tolerated without second- or third-degree AV blocks
or reduction of renal function. The present phase II study was
designed to evaluate the effects of neladenoson bialanate on car-




PANTHEON was a multicentre, randomized, placebo-controlled,
parallel-group, double-blind, dose-finding phase 2 trial to study the
efficacy, safety, pharmacokinetic and pharmacodynamic effects of the
oral partial adenosine A1 receptor agonist neladenoson bialanate over
20weeks in subjects with chronic HFrEF. The study design has been
previously reported.6 The protocol is presented in online supple-
mentary Methods S1 and the statistical analysis plan in online supple-
mentary Methods S2. The trial was approved by the ethics commit-
tee at each study centre. All the patients provided written informed
consent. This trial was registered with ClinicalTrials.gov, identifier
NCT02992288.
Patient population
The complete list of inclusion and exclusion criteria were pub-
lished previously.6 In brief, eligible patients had stable chronic
HF with a left ventricular ejection fraction (LVEF) ≤ 35% and
either (i) an episode of worsening HF within 3 months prior to
enrolment with B-type natriuretic peptide (BNP) ≥100 pg/mL or



















































































.. or BNP ≥ 300 pg/mL or NT-proBNP ≥ 1200 pg/mL (atrial fibril-
lation), or (ii) at any time in the past 4weeks, had documented
BNP ≥ 300 pg/mL or NT-proBNP ≥1200 pg/mL (sinus rhythm) or
BNP ≥ 600 pg/mL or NT-proBNP ≥ 2400 pg/mL (atrial fibrillation).
Main exclusion criteria were acute de novo HF and any cause of
chronic HF other than ischaemic cardiomyopathy or idiopathic dilated
cardiomyopathy.
Study endpoints
The complete list of study endpoints of PANTHEON has been pub-
lished previously.6 The primary endpoints were change in LVEF (%) as
measured by echocardiography and in NT-proBNP between baseline
and 20weeks (end of treatment). The secondary endpoints were
change in left ventricular end-systolic (LVESV) and end-diastolic vol-
ume (LVEDV) from baseline and high-sensitivity troponin T (hs-TnT)
from baseline to 20weeks, and cardiovascular (CV) mortality, HF
hospitalization, and urgent visits for HF as clinical outcomes. Key
exploratory endpoints were (i) weekly means of daily mean duration
in hours, of hourly intensity in gravitational units, of daily mean inten-
sity in percentage, of daily maximum intensity in percentage (measured
with the AVIVO™ patch); (ii) change in renal function, and (iii) change
in quality of life, measured by both the Kansas City Cardiomyopathy
Questionnaire (KCCQ) and the EuroQol 5 dimensions instrument
(EQ-5D-5L).
The Medtronic AVIVO™Mobile Cardiac Telemetry System provides
continuous monitoring of symptomatic and asymptomatic cardiac
arrhythmias and was implemented as a safety monitoring tool for this
trial. The device is also equipped with an accelerometer and measures
patient’s physical activity in an hourly basis. Activity outputs were
reported in gravitational unit and as a percentage of the patient’s activity
intensity compared to that of a healthy young male volunteer. The
patch was applied to the patient’s chest for seven consecutive days:
at screening and four times during treatment (baseline, week 4, week
8, and week 19).
Statistical analysis
To evaluate the primary and secondary outcomes in both studies,
we combined a multiple comparison procedure (MCP) with modelling
techniques under model uncertainty (the MCP-Mod approach) in two
key steps.6,7 Step 1 was a one-sided multiple contrast test for a
non-flat, favourable dose–response curve while controlling for type
1 error (𝛼 = 5%). A set of five candidate shapes (a linear model, an
Emax model, sigmoidal Emax models 1 and 2, and a quadratic model)
was pre-defined to cover both plausible and diverse dose–response
profiles. Step 2 was the estimation step: if a dose–response signal
was established in step 1, a dose–response model and target dose(s)
of interest was to be estimated. A dose–response signal is shown in
the primary efficacy analysis if at least one of the two null hypotheses
related to the primary efficacy variables can be rejected. The Hochberg
(step-up) procedure was applied to control the family-wise error rate.
No multiplicity adjustment was done in analysis for further efficacy or
safety variables.
Based on the assumption of a maximum effect for absolute increase
in LVEF of 5% for a dose of neladenoson bialanate, an absolute increase
of ≤ 2% under placebo, and a standard deviation of 7%, an overall
sample size of 288 randomly allocated patients (using a 1:2:2:2:2:3 allo-
cation ratio corresponding to the neladenoson bialanate 5, 10, 20, 30,
and 40mg dose groups and placebo) was required to ensure a minimum
power of 80% to detect the presence of a dose–response relationship.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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462 Participants enrolled
Excluded n= 35
Eligibility criteria not met n=17 
Consent withdrawal n=12 
Adverse event n=2 
Other reasons* n=4 
106 Randomized to 
receive placebo
427 Randomized  
37 Randomized to 
receive neladenoson 
5 mg
73 Randomized to 
receive neladenoson 
20 mg** 
70 Randomized to 
receive neladenoson 
10 mg
69 Randomized to 
receive neladenoson 
30 mg
























Withdrawal by subject=5 
Death= 1 















47 valid for PPS 
LVEF 












19 valid for PPS 
LVEF 
29 valid for PPS
35 valid for PPS 
LVEF 
58 valid for PPS
47 valid for PPS 
LVEF 
59 valid for PPS
40 valid for PPS 
LVEF 
53 valid for PPS
38 valid for PPS 
LVEF 
56 valid for PPS
NT-proBNP NT-proBNP NT-proBNP NT-proBNP NT-proBNP 
Figure 1 Consort diagram. LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PPS, per-protocol
set. *Other reasons were: logistical difficulties, physician decision, and technical problems. **One subject in the 20 mg arm never took study
drug after randomization.
This power calculation was based on simulations that use all five can-
didate models considered for dose–response modelling. Taking into
account both primary outcomes in PANTHEON, simulations showed
that the power to reject at least one of the two primary null hypothe-
ses was 83%. The primary analysis of primary and secondary end-
points was performed on the respective per-protocol sets (PPS). Sub-
jects were excluded from both PPS if they presented validity findings.
For the LVEF PPS and NT-proBNP PPS, subjects without baseline or
end-of-treatment values for LVEF and NT-proBNP, respectively, were
excluded with the exception of ‘compliant and adherent’ patients who
were ‘censored’ due to CV death or a hospitalization for HF preventing
the assessment of the relevant efficacy endpoints 20weeks after ran-
domization to take place as planned. For missing post-baseline value
due to CV death or study drug/study discontinuation due to HF, a worst
case approach was applied, i.e. for each dose group the worse observed
value (WOV) in that group was entered as post-baseline value.8
The LVEDV and LVESV results were also analysed in the LVEF PPS.
The missing values of post-baseline of LVESV and LVEDV were imputed
by WOV if the baseline values were not missing and the subjects have
CV death or HF hospitalization, otherwise remained missing. Hs-TnT
values were analysed in the NT-proBNP PPS. Similarly as for the pri-
mary efficacy variables and for LVESV and LVEDV, the missing values of
post-baseline of hs-TnT were imputed by WOV if the baseline values
were not missing and the subjects had CV death or HF hospitalization,
otherwise remained missing. The distribution of subjects PPS
and per-dose group is displayed in Figure 1. Post-hoc analysis on
exploratory parameters described in this document was performed






































. last observation carried forward approach for missing data. Analysis
of safety data was performed on the safety analysis set including all
patients who took at least one dose of study drug, without imputation.
Data sharing statement
Bayer has granted Groningen University access to anonymized patient
level data from the neladenoson bialanate phase IIb clinical studies, via




From 22 February 2017 to 28 March 2018, a total of 462 patients
were enrolled at 92 centres in 11 countries (USA, Belgium, Ger-
many, Greece, Italy, Netherlands, Spain, Bulgaria, Poland, Israel,
and Japan –for the complete list of participating sites and principal
investigators see online supplementary Methods S4). A total of
35 patients were excluded as screen failures, mostly related to
violation of eligibility criteria. Accordingly, 427 patients were
randomized to neladenoson bialanate 5, 10, 20, 30, and 40mg
dose groups or placebo (Figure 1). Table 1 shows that the groups
were balanced with respect to baseline characteristics. Mean age
of the patients was 67 years, 17% was female, mean LVEF was 28%,
median NT-proBNP was 2085 ng/L, 62% had ischaemic HF, 38%
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 66.9 66.6 66.4 68.1 67.6 67.5 67.2
Female sex 18 (17.0%) 9 (24.3%) 11 (15.7%) 14 (19.2%) 12 (17.4%) 7 (9.7%) 71 (16.6%)
Race
White 98 (92.5%) 32 (86.5%) 65 (92.9%) 66 (90.4%) 64 (92.8%) 65 (90.3%) 390 (91.3%)
Black 2 (1.9%) 2 (5.4%) 2 (2.9%) 2 (2.7%) 2 (2.9%) 2 (2.8%) 12 (2.8%)
Asian 6 (5.7%) 3 (8.1%) 3 (4.3%) 5 (6.8%) 3 (4.3%) 5 (6.9%) 25 (5.9%)
Region
North America 4 (3.8%) 4 (10.8%) 6 (8.6%) 1 (1.4%) 3 (4.3%) 4 (5.6%) 22 (5.2%)
Western Europe and Israel 57 (53.8%) 15 (40.5%) 27 (38.6%) 38 (52.1%) 45 (65.2%) 40 (55.6%) 222 (52.0%)
Eastern Europe 39 (36.8%) 15 (40.5%) 35 (50.0%) 29 (39.7%) 18 (26.1%) 23 (31.9%) 159 (37.2%)
Asia 6 (5.7%) 3 (8.1%) 2 (2.9%) 5 (6.8%) 3 (4.3%) 5 (6.9%) 24 (5.6%)
Vital signs
SBP (mmHg, mean) 117.3 117 117.5 119.6 121.5 117.6 118.5
HR (bpm, mean) 70.1 69.3 70 69.8 68.3 70.7 69.8
BMI (kg/m2, mean) 27.8 28.3 28.5 27 27.9 28.5 27.9
GFR (ml/min/1.73m2, mean) 61.8 60.7 60.5 63.2 58.9 59.8 60.2
Clinical features of HF
LVEF (%) 28.24 26.22 27.58 29.7 29.87 26.24 28.18
NT-proBNP (pg/mL, median) 2111 2071 2063 1894.5 2084 2419 2085
NYHA class I 0 0 1 (1.4%) 0 0 0 1 (0.2%)
NYHA class II 62 (58.5%) 23 (62.2%) 38 (54.3%) 44 (60.3%) 49 (71.0%) 49 (68.1%) 265 (62.1%)
NYHA class III/IV 44 (41.5%) 14 (37.8%) 31 (44.3%) 29 (39.7%) 20 (29.0%) 23 (31.9%) 161 (37.7%)
Ischaemic cardiomyopathy 65 (61.3%) 25 (67.6%) 45 (64.3%) 50 (68.5%) 37 (53.6%) 42 (58.3%) 264 (61.8%)
Medical history
Hypertension 63 (59.4%) 22 (59.5%) 39 (55.7%) 47 (64.4%) 40 (58.0%) 44 (61.1%) 255 (59.7%)
Diabetes mellitus 45 (42.5%) 15 (40.5%) 23 (32.9%) 36 (49.3%) 23 (33.3%) 26 (36.1%) 168 (39.3%)
Atrial fibrillation 44 (41.5%) 14 (37.8%) 27 (38.6%) 26 (35.6%) 27 (39.1%) 33 (45.8%) 171 (40.0%)
Concomitant medication of interest (%)
ACEi 55 51 59 56 52 63 56
ARB 14 16 16 19 13 13 15
ARNI 19 19 13 12 17 17 16
MRA 88 89 80 82 81 79 83
Beta-blocker 97 100 94 96 97 96 97
Loop diuretics 94 92 94 95 91 96 94
Ivabradine 7 11 10 7 9 13 9
CRT-D 11 16 18 20 20 17 17
ICD 34 30 31 22 22 21 27
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; BMI, body mass index; CRT-D, cardiac
resynchronization therapy with defibrillation; GFR, glomerular filtration rate; HF, heart failure; HR, heart rate; ICD, implantable cardioverter defibrillator; LVEF, left ventricular
ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; SBP, systolic
blood pressure.
had dilated cardiomyopathy, 62% had New York Heart Association
(NYHA) class II symptoms, 40% had a history of atrial fibrillation,
and 39% had diabetes. Patients were optimally treated at baseline
(87% renin–angiotensin–aldosterone system inhibitors, 97%
beta-blockers, and 83% mineralocorticoid receptor antagonists).
Primary endpoints
Results of the primary endpoint are presented in Figure 2. The
per-protocol analysis of LVEF was done in 226 patients since
the rest of the echocardiograms were either missing or of poor

















. effect of neladenoson bialanate on the change in LVEF (P = 0.23;
lowest P-value for the linear candidate model shape). For the
per-protocol analysis of the change in NT-proBNP, 337 patients
were available with valid measurement both at baseline and at week
20. Compared with placebo, there was no dose–response effect
of neladenoson bialanate on the change in NT-proBNP (P = 0.74
lowest P-value for the Emax candidate model shape).
Secondary endpoints
Results of the change in LVESV, LVEDV and hs-TnT are presented
in online supplementary Figure S1. Overall, left ventricular volumes
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Primary endpoints. Change in (A) left ventricular ejection fraction (LVEF) and (B) N-terminal pro-B-type natriuretic peptide
(NT-proBNP). Box: 25th–75th percentile; horizontal line: median; circle: arithmetic mean; vertical lines extend from the box to a distance of
at most 1.5 interquartile ranges and any value more extreme is plotted separately. PPS, per-protocol set.
decreased during the 20weeks of the study in all treatment arms,
the decrease was more evident in the 5 and the 40mg groups for
both LVESV (21mL and 15mL, respectively) and LVEDV (21mL
and 19mL, respectively), whereas the other dose groups showed
less decrease compared to placebo where a mean decrease of
5 mL in LVESV and of 13mL in LVEDV was observed. There was
no dose–response effect of neladenoson bialanate on the change
in LVESV (P = 0.46 lowest P-value for the linear candidate model
shape) and LVEDV (P = 0.57 lowest P-value for the linear candidate
model shape). Results of log-transformed hs-TnT showed no
decreasing dose–response relationship (P = 0.99 lowest P-value
for the SigmoidalEmax2 candidate model shape). The time to the
composite clinical event of CV death and hospitalization or urgent
visit for HF is presented in Figure 3. Although the highest event rate
was observed in patients receiving placebo, and the lowest event
rate was observed in patients receiving the highest (40mg) dose
of neladenoson bialanate, in the full analysis set, this difference was
numerically small and not statistically significant.
Exploratory endpoints
Activity
Activity was measured by the AVIVO device and analysis was
performed on the weekly mean activity intensity assessed in
gravitational units as well as assessed in percentage of the activity of
a healthy male; and weekly activity duration in hours. No changes
from baseline in either duration or intensity of activity across any












































Exploratory analyses revealed that the percentage of patients
with an increase in LVEF ≥ 5 points compared to baseline was
higher in the active arms vs. placebo. However, no dose-dependent
trend was observed. In addition, a decrease in mitral valve E
wave peak velocity in the active arms compared to placebo was
noted, but the decrease was not dose-dependent. The remaining
relevant echocardiography parameters showed no dose-dependent
change.
Renal function
We observed a dose-dependent decrease in renal function with
increasing doses of neladenoson bialanate. Online supplemen-
tary Figure S2 shows a statistically significant dose-dependent
decrease in estimated glomerular filtration rate (eGFR) between
baseline and 20weeks of treatment (P = 0.0014 in the linear
candidate model shape). In addition, when eGFR was depicted
against the measured plasma concentration of BAY 84-2174, we
found an exposure dependent decrease in eGFR with increasing
plasma concentrations of BAY 84-2174. Similarly, plasma cystatin
C was increased in all dosages vs. placebo and this increase was
exposure-dependent as well.
Quality of life
We observed a borderline nominally significant dose-dependent
(P = 0.04 for the linear candidate model shape) improvement
of approximately four points compared to placebo in the
KCCQ Overall Summary Score. This change from baseline
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Kaplan–Meier survival curves of the composite clinical endpoint of cardiovascular death and hospitalization or urgent visit for heart
failure.
was exposure-dependent. The observed change was mainly driven
by the social limitation domain and to a lesser extent by physical
limitation domain. We found no dose-dependent change in the
EQ-5D-5L visual analogue scale score.
Safety
Safety data are presented in Table 2. The incidence rates of adverse
events (AE), drug-related AEs, serious AEs and drug-related seri-
ous AEs in subjects treated with placebo or neladenoson bialanate
were similar in all groups. The majority of AEs and drug-related AEs
in all groups were of mild to moderate intensity. We found numer-
ically less deaths in the pooled neladenoson bialanate group (3.4%)
vs. placebo (6.6%). Hypotension was reported more frequent in
the pooled neladenoson bialanate groups (5.6%) vs. placebo (0.9%).
There was no exposure-dependent change in systolic blood pres-
sure, but a modest yet statistically significant decrease in dias-
tolic blood pressure with increasing plasma concentrations of BAY
84-2174 (P = 0.0055) was noted. The proportion of subjects with
AEs ‘renal impairment’ was higher in the pooled neladenoson group
(8.4%) vs. placebo (5.7%) and serious AEs belonging to the renal
and urinary disorders group were also more frequently reported in
the pooled neladenoson bialanate groups (5.9%) vs. placebo (3.8%),
corroborating with both findings of dose-dependent decrease in
eGFR and increase in cystatin C. There were three complete AV
blocks in the pooled neladenoson bialanate groups and none in
the placebo group. No symptomatic bradycardias were reported.
There were no clinically relevant differences in the groups with
regard to PR duration, QTc prolongation, ventricular tachyarrhyth-
mias (online supplementary Table S1). However, on a post-hoc
analysis performed with last observation carried forward for miss-
















































. in the Emax candidate model shape) decrease in heart rate from
baseline to week 20 (online supplementary Figure S3). A decrease of
an average of 2 bpm at the 40mg dose group was demonstrated by
the AVIVO monitoring device assessing weekly measures of 5 min
intervals during day time from screening (i.e. the week prior to
study drug intake) to the last week of treatment (week 19) (online
supplementary Table S2), however no dose-dependent trend could
be observed in this descriptive analysis.
The study drug was discontinued in 59 participants (13.8%) in
total. Treatment discontinuation rate was highest in the 40mg
group (13 participants, 18%), followed by the placebo group (17
participants, 16%). The 5 mg group had 5 (13.5%) discontinuations,
followed, in decreasing order, by the 20mg (n= 9; 12%), 30mg
(n= 8; 11%), and 10 mg (n= 7; 10%) groups. Overall there was
no pattern of AEs leading to discontinuation among the study
groups.
Discussion
PANTHEON tested the hypothesis that the partial adenosine A1
receptor agonist neladenoson bialanate improves cardiac function
and thereby reduces levels of NT-proBNP in patients with
HFrEF. However, PANTHEON demonstrated no dose-dependent
improvements in LVEF and NT-proBNP nor any other effects
on left ventricular volumes or hs-TnT or cardiovascular mortal-
ity, HF hospitalization, and urgent visits for HF. We observed a
dose-dependent decrease in renal function and heart rate, and
a modest decrease in (diastolic) blood pressure. Therefore, the
hypothesis that a partial adenosine A1 receptor agonist limits
undesired cardiac conduction and renal disorders compared to a
full agonist, while preserving its effects on cardiac function, must
be rejected.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Adverse events and serious adverse events in patients treated with placebo or neladenoson bialanate,
5–40mg/day, by medical dictionary for regulatory activities version 21.0 preferred term
Events Neladenoson bialanate Total














. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Any adverse events 71 (67.0%) 28 (75.7%) 48 (68.6%) 47 (65.3%) 53 (76.8%) 56 (77.8%) 303 (71.1%)
Mild 29 (27.4%) 15 (40.5%) 16 (22.9%) 20 (27.8%) 21 (30.4%) 24 (33.3%) 125 (29.3%)
Moderate 27 (25.5%) 11 (29.7%) 21 (30.0%) 22 (30.6%) 20 (29.0%) 22 (30.6%) 123 (28.9%)
Severe 15 (14.2%) 2 (5.4%) 11 (15.7%) 5 (6.9%) 12 (17.4%) 10 (13.9%) 55 (12.9%)
Any serious adverse events 31 (29.2%) 13 (35.1%) 28 (40.0%) 22 (30.6%) 28 (40.6%) 26 (36.1%) 148 (34.7%)
Any drug-related adverse events 14 (13.2%) 7 (18.9%) 10 (14.3%) 12 (16.7%) 7 (10.1%) 11 (15.3%) 61 (14.3%)
Any drug-related serious adverse events 4 (3.8%) 0 1 (1.4%) 3 (4.2%) 1 (1.4%) 1 (1.4%) 10 (2.3%)
Any adverse events resulting in death 7 (6.6%) 1 (2.7%) 5 (7.1%) 1 (1.4%) 2 (2.9%) 2 (2.8%) 18 (4.2%)
Discontinued due adverse events 8 (7.5%) 1 (2.7%) 2 (2.9%) 2 (2.8%) 2 (2.9%) 7 (9.7%) 22 (5.2%)
Discontinued due to serious adverse events 5 (4.7%) 0 2 (2.9%) 0 1 (1.4%) 4 (5.6%) 12 (2.8%)
Renal and urinary disorders 4 (3.8%) 2 (5.4%) 2 (2.9%) 3 (4.2%) 3 (4.3%) 9 (12.5%) 23 (5.4%)
Acute kidney injury 2 (1.9%) 0 0 1 (1.4%) 1 (1.4%) 2 (2.8%) 6 (1.4%)
Chronic kidney disease 2 (1.9%) 1 (2.7%) 0 0 0 2 (2.8%) 5 (1.2%)
Renal failure 0 0 0 1 (1.4%) 0 2 (2.8%) 3 (0.7%)
Renal impairment 0 1 (2.7%) 2 (2.9%) 1 (1.4%) 2 (2.9%) 3 (4.2%) 9 (2.1%)
Adverse events occurring in ≥4% patients overall
Cardiac failure 22 (20.8%) 7 (18.9%) 12 (17.1%) 7 (9.7%) 11 (15.9%) 13 (18.1%) 72 (16.9%)
Renal impairment 6 (5.7%) 2 (5.4%) 2 (2.9%) 5 (6.9%) 8 (11.6%) 10 (13.9%) 33 (7.7%)
Hypotension 1 (0.9%) 1 (2.7%) 6 (8.6%) 5 (6.9%) 3 (4.3%) 3 (4.2%) 19 (4.5%)
Ventricular tachycardia 4 (3.8%) 2 (5.4%) 3 (4.3%) 3 (4.2%) 3 (4.3%) 2 (2.8%) 17 (4.0%)
Adverse events leading to discontinuation in >1 subject
Cardiac failure 3 (2.8%) 0 2 (2.9%) 0 0 1 (1.4%) 5 (1.2%)
Headache 1 (0.9%) 1 (2.7%) 0 0 1 (1.4%) 0 3 (0.7%)
Hypotension 1 (0.9%) 0 0 1 (1.4%) 0 0 2 (0.5%)
Patients in PANTHEON reflected a typical stable chronic HF
population. With a mean LVEF of 28% and a mean NT-proBNP
of 2085 ng/L, there was sufficient room for improvement of both
primary outcomes with neladenoson bialanate. However, the anal-
ysis of LVEF as a primary outcome in the PPS was limited by the high
number of missing echocardiograms or those of insufficient quality.
Patients in PANTHEON were treated according to current HFrEF
guidelines, with 87% on a renin–angiotensin–aldosterone system
inhibitor, 97% on a beta-blocker, and 83% on a mineralocorticoid
receptor antagonist.
The dose-related impairment in renal function was a consis-
tent finding with multiple renal function parameters. Estimated
GFR was reduced up to a mean of −9 mL/min/1.73m2 in the
highest dose. This decrease in eGFR is likely related to adeno-
sine A1 receptor activation in the kidney, which is responsible for
modulation of the tubulo-glomerular feedback at the level of the
macula densa.3 Through renal vas afferens contraction, adenosine
causes a decrease in renal blood flow. Adenosine A1 antagonists
have consistently shown to improve renal function in smaller clini-
cal mechanistic studies,9 but the adenosine A1 receptor antagonist
rolofylline failed to improve renal function and clinical outcome in
a large phase II trial.10
A mean decrease in heart rate of up to 3–4 bpm was observed
in the neladenoson bialanate groups compared to placebo. This




































.. symptomatic bradycardia in any treatment arm. A decrease in
heart rate with neladenoson bialanate was expected, since it is a
well-known effect of adenosine.
We found a modest, but statistically significant dose-dependent
improvement in quality of life, when measured by the Overall
Summary Score of the KCCQ. However, in contrast to what was
expected, this result was mainly driven by the Social Score and not
by the Symptoms Score. In addition, the data were inconsistent
with the quality of life data from the EQ-5D-5L questionnaire. We
therefore believe that this was a chance finding.
The most frequently reported AE in this study was worsening
HF, and the distribution of such events was numerically similar
in all treatment groups with slightly lower incidence in the active
arms in comparison to the placebo group. However, the incidence
of worsening renal function was more frequently reported in the
two higher dose groups in comparison to placebo, which reflects
the increase in creatinine previously described. AEs of special
safety interest were defined as second-degree AV block leading to
change in therapy or discontinuation of study drug, third-degree
AV block, or symptomatic bradycardia. Only very few of those
events were reported without any significant difference between
groups.
PANTHEON was conducted based on the reported beneficial
mechanistic cardiac effects of adenosine, the beneficial cardiac
effects of a partial adenosine A1 receptor agonist in a dog model,4
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and the finding that neladenoson bialanate appeared to be safe in
two small early phase studies in patients with HF.5 Partial adenosine
A1 agonism was expected to maintain the beneficial cardiac effects
while avoiding the deleterious effects on renal function and AV
conduction. Unfortunately, beneficial cardiac effects could not be
demonstrated while we observed a consistent impairment in renal
function. The discrepancy between outcomes in animal models
compared to clinical studies is well known, and was observed
with this agent as well. This discrepancy might be related to
several factors, such as pre-existent disease (e.g. atherosclerosis),
co-morbidities, and background therapies. Taken together, these
data do not support further development of partial adenosine A1
receptor agonists for the treatment of HFrEF.
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